Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EBIT (2019 - 2025)

C4 Therapeutics' EBIT history spans 7 years, with the latest figure at -$23.1 million for Q4 2025.

  • For Q4 2025, EBIT rose 38.62% year-over-year to -$23.1 million; the TTM value through Dec 2025 reached -$115.2 million, up 3.67%, while the annual FY2025 figure was -$115.2 million, 3.67% up from the prior year.
  • EBIT reached -$23.1 million in Q4 2025 per CCCC's latest filing, up from -$34.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$15.3 million in Q4 2021 to a low of -$38.3 million in Q4 2022.
  • Average EBIT over 5 years is -$29.3 million, with a median of -$28.8 million recorded in 2025.
  • Peak YoY movement for EBIT: plummeted 151.02% in 2022, then soared 42.92% in 2024.
  • A 5-year view of EBIT shows it stood at -$15.3 million in 2021, then tumbled by 151.02% to -$38.3 million in 2022, then rose by 2.26% to -$37.4 million in 2023, then fell by 0.75% to -$37.7 million in 2024, then skyrocketed by 38.62% to -$23.1 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's EBIT are -$23.1 million (Q4 2025), -$34.4 million (Q3 2025), and -$28.5 million (Q2 2025).